MY185481A - Osteoclast inhibitors for pain - Google Patents
Osteoclast inhibitors for painInfo
- Publication number
- MY185481A MY185481A MYPI2016704377A MYPI2016704377A MY185481A MY 185481 A MY185481 A MY 185481A MY PI2016704377 A MYPI2016704377 A MY PI2016704377A MY PI2016704377 A MYPI2016704377 A MY PI2016704377A MY 185481 A MY185481 A MY 185481A
- Authority
- MY
- Malaysia
- Prior art keywords
- pain
- osteoclast inhibitors
- osteoclast
- inhibitors
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
Applications Claiming Priority (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201414228241A | 2014-05-27 | 2014-05-27 | |
US14/288,713 US8901162B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,716 US8835650B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,720 US8865757B1 (en) | 2014-05-28 | 2014-05-28 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US201462012112P | 2014-06-13 | 2014-06-13 | |
US14/310,811 US8822436B1 (en) | 2012-05-14 | 2014-06-20 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US14/336,642 US20140329773A1 (en) | 2012-05-14 | 2014-07-21 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease |
US14/446,184 US9006279B1 (en) | 2014-01-30 | 2014-07-29 | Substituted imidazolium compounds for treating disease |
PCT/US2014/050427 WO2015060924A1 (en) | 2013-10-25 | 2014-08-08 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US14/457,659 US20140349974A1 (en) | 2014-08-12 | 2014-08-12 | Zoledronic acid dosage forms for the treatment of pain |
US14/481,097 US8962599B1 (en) | 2014-05-27 | 2014-09-09 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US201462053619P | 2014-09-22 | 2014-09-22 | |
US14/495,732 US9127069B1 (en) | 2014-06-11 | 2014-09-24 | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US14/530,556 US20150051175A1 (en) | 2012-05-14 | 2014-10-31 | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain |
US14/536,526 US20150057250A1 (en) | 2012-05-14 | 2014-11-07 | Inhibitors of osteoclast activity for treating arthritis |
US14/538,709 US9290575B2 (en) | 2014-06-11 | 2014-11-11 | Compositions comprising RANK/RANKL antagonists and related compounds for treating pain |
US14/540,333 US9216168B1 (en) | 2014-05-27 | 2014-11-13 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US14/604,524 US9211257B2 (en) | 2012-05-14 | 2015-01-23 | Osteoclast inhibitors for knee conditions |
US14/605,822 US9216153B2 (en) | 2012-05-14 | 2015-01-26 | Osteoclast inhibitors for knee conditions |
US14/607,985 US9289385B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/607,947 US9289384B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/608,855 US9079927B1 (en) | 2014-05-27 | 2015-01-29 | Substituted imidazolium compounds for treating disease |
US14/625,457 US9427403B2 (en) | 2012-05-14 | 2015-02-18 | Methods for the safe administration of imidazole or imidazolium compounds |
US201562127214P | 2015-03-02 | 2015-03-02 | |
US14/635,857 US9283239B2 (en) | 2012-05-14 | 2015-03-02 | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US14/639,013 US9289441B2 (en) | 2014-08-08 | 2015-03-04 | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US14/686,551 US9408860B2 (en) | 2012-05-14 | 2015-04-14 | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
PCT/US2015/032739 WO2015184003A1 (en) | 2014-05-27 | 2015-05-27 | Osteoclast inhibitors for pain |
Publications (1)
Publication Number | Publication Date |
---|---|
MY185481A true MY185481A (en) | 2021-05-19 |
Family
ID=57483086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2016704377A MY185481A (en) | 2014-05-27 | 2015-05-27 | Osteoclast inhibitors for pain |
Country Status (3)
Country | Link |
---|---|
AU (3) | AU2017213506B2 (en) |
CA (3) | CA3194798A1 (en) |
MY (1) | MY185481A (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2849758T3 (en) * | 2012-05-14 | 2018-05-14 | Antecip Bioventures Ii Llc | COMPOSITIONS INCLUDING ZOLEDRONIC ACID OR RELATED COMPOUNDS TO RELIEVE INFLAMMATORY Pain and RELATED CONDITIONS |
-
2015
- 2015-05-27 CA CA3194798A patent/CA3194798A1/en active Pending
- 2015-05-27 CA CA3114271A patent/CA3114271C/en active Active
- 2015-05-27 CA CA2950443A patent/CA2950443A1/en not_active Abandoned
- 2015-05-27 MY MYPI2016704377A patent/MY185481A/en unknown
-
2017
- 2017-08-10 AU AU2017213506A patent/AU2017213506B2/en active Active
- 2017-12-06 AU AU2017272199A patent/AU2017272199B2/en active Active
-
2019
- 2019-06-27 AU AU2019204559A patent/AU2019204559B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017272199A1 (en) | 2017-12-21 |
AU2017213506B2 (en) | 2017-09-07 |
CA3194798A1 (en) | 2015-12-03 |
CA3114271A1 (en) | 2015-12-03 |
AU2017272199B2 (en) | 2019-03-28 |
AU2019204559B2 (en) | 2020-04-16 |
AU2019204559A1 (en) | 2019-07-18 |
CA2950443A1 (en) | 2015-12-03 |
CA3114271C (en) | 2023-06-06 |
AU2017213506A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2541571A (en) | Pharmaceutical compositions | |
MX2018006578A (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions. | |
EA201591509A1 (en) | CDC7 INHIBITORS | |
MX2017003516A (en) | Pyrazole derivatives as sgc stimulators. | |
NZ724691A (en) | Quinoline derivatives as smo inhibitors | |
EA201791133A1 (en) | ERK INHIBITORS | |
WO2014165090A8 (en) | Compounds for the treatment of tuberculosis | |
MX2018006632A (en) | Bicyclic inhibitors of pad4. | |
SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
EP3226972A4 (en) | Methods and compositions for treating migraine and conditions associated with pain | |
MX2017000306A (en) | Methods for treating hypotension. | |
MX2017016114A (en) | Methods of treating or preventing a proteopathy. | |
NZ722600A (en) | Methods of treating mild brain injury | |
MX2016009655A (en) | Novel methods for treating cancer. | |
HK1244211A1 (en) | Method for treating, preventing, or reducing the risk of skin infection | |
ZA201703467B (en) | Methods of treating ocular conditions | |
JO3541B1 (en) | Medical treatments based on anamorelin | |
MX2020009966A (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine. | |
MX2018005987A (en) | Heterocyclic compounds for the treatment of disease. | |
MX2018003301A (en) | Pcna inhibitors. | |
PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
MX2021008225A (en) | Compositions and methods for treatment of abnormal cell growth. | |
EP3193610A4 (en) | Selective nav1.7 inhibitors for the treatment of diabetes | |
MX2017007318A (en) | Methods of preventing, reducing or treating macular degeneration. |